All stock lists
Axsome Therapeutics, Inc. (NASDAQ:AXSM)
US · Delayed Price · Currency is USD
Also listed: 0HKF.LHealthcare · Biotechnology
144.06-0.98 (-0.68%)
Market cap
$7.55B
Health Score
Analyst consensus
Listed since
Nov 19, 2015
Website
Insider Score
––Not scored
AXSM Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
AXSM analyst forecast
AXSM analyst consensus
Moderate Buy10 ratings
Buy 9 Hold 1 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
AXSM 12-month price target
$285.00+97.8% upsideaverage of 1 firm
$285.00High
$285.00Low
Best analysts covering AXSM
- Needham100%success rate · 15 calls
- RBC Capital100%success rate · 14 calls
- Truist Securities100%success rate · 4 calls
- Baird100%success rate · 4 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
AXSM analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-10-08 |
| — | Deutsche Bank | Buy | — | — | Reiterated | 2026-09-29 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2026-09-25 |
| — | Truist Securities | Buy | — | — | Reiterated | 2026-09-23 |
| Truist Financial | — | $285.00 | +40.3% | — | 2026-09-23 | |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2026-09-18 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-08-31 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-08-12 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-08-11 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-08-11 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-08-11 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2026-08-11 |
| — | Needham | Buy | — | — | Reiterated | 2026-08-11 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-07-31 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-07-15 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-07-08 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-07-07 |
| — | TD Cowen | Buy | — | — | Reiterated | 2026-06-17 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-05-05 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-05-05 |
| — | Baird | Outperform | — | — | Reiterated | 2026-05-05 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-05-05 |
| — | Needham | Buy | — | — | Reiterated | 2026-05-05 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-05-05 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-05-05 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2026-05-05 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-05-04 |
| — | Jefferies | Buy | — | — | Reiterated | 2026-05-04 |
| — | Needham | Buy | — | — | Reiterated | 2026-05-01 |
| — | UBS | Buy | — | — | Reiterated | 2026-04-10 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-03-25 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-02-24 |
| — | UBS | Buy | — | — | Reiterated | 2026-02-24 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-02-24 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-02-24 |
| — | Needham | Buy | — | — | Reiterated | 2026-02-23 |
| — | Jefferies | Buy | — | — | Reiterated | 2026-02-03 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2026-01-28 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-01-21 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-01-20 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2026-01-16 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-01-13 |
| — | Morgan Stanley | Equal Weight | — | — | Downgraded | 2026-01-08 |
| — | UBS | Buy | — | — | Reiterated | 2026-01-06 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-01-05 |
| — | Needham | Buy | — | — | Reiterated | 2025-12-31 |
| — | Mizuho | Outperform | — | — | Reiterated | 2025-11-06 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-11-04 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-11-04 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-11-04 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-11-04 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-11-04 |
| — | Needham | Buy | — | — | Reiterated | 2025-11-04 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-10-20 |
| — | UBS | Buy | — | — | Reiterated | 2025-08-06 |
| — | B of A Securities | Buy | — | — | Reiterated | 2025-08-05 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-08-05 |
| — | Needham | Buy | — | — | Reiterated | 2025-08-04 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-06-12 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-06-10 |
AXSM earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-23 | -0.70 | -0.71 | $193.4M | $194.7M |
| 2026-05-04 | -0.85 | -1.26 | $190.9M | $189.4M |
| 2026-08-10 | -0.89 | -0.99 | $221.1M | $216.4M |
| 2026-11-02 | -0.63 | 0.00 | $250.2M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.